Sanofi has launched a gene editing clinical trial for sickle cell disease, using CRISPR technology to modify the faulty gene responsible for the condition.
The Trial
The trial will involve patients with severe sickle cell disease, who will undergo gene editing to correct the faulty gene.
The CRISPR technology has shown an 80% success rate in preclinical trials, offering hope for a potential cure.